Bringing Therapies to Patients When Standard Channels Fail
When the medicine a patient needs is unavailable, unlicensed locally, or in shortage, treatment can stall.
We facilitate compliant access, delivering to hospitals, care centers, and pharmacies when no standard route exists. This includes coordinating the right pathway, assembling documentation, managing authority interactions, and delivering temperature-controlled products with full traceability.
Access to essential medicines often faces regulatory and supply barriers. Our treatment access solutions enable global access to locally unlicensed therapies, address temporary shortages, and support cross-border supply.
We help innovative treatments reach the point of care when standard channels fall short, because getting therapy to the patients who need them is what matters most.
We enable global, safe and compliant access to treatment.
Our Treatment Access Solutions
Individual ImportPatient-Specific Access to Non-Marketed Innovations. Expands care options with compliant access to innovative therapies approved outside the local market for clinically justified cases.
Shortage ResolutionRestore continuity of care during supply disruptions. Proactive market scanning, authority collaboration, qualified alternatives, and controlled distribution to keep care sites supplied.
Regulatory Landscape GuidancePractical clarity on country-specific routes to treatment access. Hands-on enablement across countries: regulatory guidance to move cases from request to pharmacy receipt.
Why Komtur?
Patient-First, Care-Centric Handling
Single case owner, transparent status, and checklist documentation help keep cases moving and care continuous.
Speed with Certainty
Bonded-warehouse release, established customs and Importer of Record (IOR) workflows, and temperature-controlled last-mile delivery to hospital or pharmacy receipt.
Licensed Global Access Network
Quality-assured sourcing with falsified-medicines safeguards, serialization, and end-to-end batch traceability.
Authority-Aligned, Multi-Country Enablement
Correct use of named-patient and shortage pathways, plus practical broker and IOR guidance as well as documentation support.
Proactive Access Insights
Continuous shortage and regulatory-approval monitoring, demand validation, and early qualification of alternatives to protect continuity of care.
“Most access cases fail in the gaps between regulation, documentation, and logistics. Closing those gaps is what keeps treatment moving.”
Branded Drugs
Branded Drugs
Market access, distribution control, and lifecycle management vary significantly across regions.
Branded Drugs
Originator medicines approved for clinical use and protected by intellectual property rights.
Post-launch success depends on controlled distribution, regulatory alignment, and continuity across diverse healthcare systems.
Generics
Generics
Supply stability and substitution dynamics must be managed across pricing and reimbursement pressures.
Generics
Medicinal products equivalent to originators following patent expiry.
Availability, sourcing reliability, and local substitution rules directly impact treatment continuity and access.
Orphan & Ultra-Orphan Drugs
Orphan & Ultra-Orphan Drugs
Access depends on navigating fragmented regulations, small patient populations, and limited supply.
Orphan & Ultra-Orphan Drugs
Access depends on navigating fragmented regulations, small patient populations, and limited supply.
Biosimilars
Biosimilars
Adoption depends on regulatory acceptance, clinical confidence, and structured market access pathways.
Biosimilars
Biologic medicines highly similar to approved reference products.
Successful use requires alignment across regulatory documentation, stakeholder acceptance, and controlled integration into clinical practice.
Cell & Gene Therapy (ATMPs)
Cell & Gene Therapy (ATMPs)
Delivery depends on strict control of identity, timing, and site readiness at every step.
Cell & Gene Therapy (ATMPs)
Advanced therapies based on genes, cells, or engineered tissues, governed by specialised regulatory frameworks.
Chain-of-identity, cold chain integrity, and exact coordination with clinical sites are critical for safe and compliant administration.
Controlled Substances
Controlled Substances
Strict regulatory controls require secure handling, documentation, and authority coordination across all markets.
Controlled Substances
Medicinal products subject to legal restrictions due to risk of misuse or diversion.
Compliance depends on controlled storage, transport, and documentation aligned with local regulatory frameworks.
Veterinary Drugs
Veterinary Drugs
Separate regulatory frameworks and supply chains require distinct handling and compliance approaches.
Veterinary Drugs
Medicinal products used for the treatment or prevention of diseases in animals.
Where applicable, supply must align with veterinary-specific regulations and distribution channels.
Nutraceuticals
Nutraceuticals
Regulatory classification and permitted use vary widely between markets and intended applications.
Nutraceuticals
Products derived from food sources providing health or wellness benefits.
Use in clinical or access contexts depends on local regulatory acceptance and integration into care pathways.
Diagnostic Medical Devices
Diagnostic Medical Devices
Accurate data depends on seamless integration of diagnostics into clinical workflows and study design.
Diagnostic Medical Devices
Devices used to identify, stratify, or monitor patients during treatment or trials.
Operational success relies on correct deployment, training, and alignment with clinical and data collection processes.
Therapeutic Medical Devices
Therapeutic Medical Devices
Effective use depends on site readiness, training, and integration into treatment pathways.
Therapeutic Medical Devices
Devices delivering treatment through mechanical, physical, or digital means.
Implementation requires coordination across logistics, training, and clinical adoption to ensure safe and consistent use.